MA33824B1 - Agonistes du recepteur mglu2 - Google Patents

Agonistes du recepteur mglu2

Info

Publication number
MA33824B1
MA33824B1 MA34967A MA34967A MA33824B1 MA 33824 B1 MA33824 B1 MA 33824B1 MA 34967 A MA34967 A MA 34967A MA 34967 A MA34967 A MA 34967A MA 33824 B1 MA33824 B1 MA 33824B1
Authority
MA
Morocco
Prior art keywords
receptor agonists
mglu2 receptor
agonists
mglu2
schizophrenia
Prior art date
Application number
MA34967A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
James Allen Monn
Lourdes Prieto
Martinez Lorena Taboada
Salgado Carlos Montero
Bruce William Shaw
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33824(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA33824B1 publication Critical patent/MA33824B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA34967A 2009-12-21 2012-06-14 Agonistes du recepteur mglu2 MA33824B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17
PCT/US2010/060371 WO2011084437A1 (en) 2009-12-21 2010-12-15 Mglu2 agonists

Publications (1)

Publication Number Publication Date
MA33824B1 true MA33824B1 (fr) 2012-12-03

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34967A MA33824B1 (fr) 2009-12-21 2012-06-14 Agonistes du recepteur mglu2

Country Status (35)

Country Link
US (1) US8318184B2 (enExample)
EP (1) EP2516406B1 (enExample)
JP (1) JP5779190B2 (enExample)
KR (1) KR101395356B1 (enExample)
CN (1) CN102695701B (enExample)
AR (1) AR079343A1 (enExample)
AU (1) AU2010340039B2 (enExample)
BR (1) BR112012017188B1 (enExample)
CA (1) CA2784667C (enExample)
CR (1) CR20120322A (enExample)
CY (1) CY1114880T1 (enExample)
DK (1) DK2516406T3 (enExample)
DO (1) DOP2012000173A (enExample)
EA (1) EA020229B1 (enExample)
EC (1) ECSP12011989A (enExample)
ES (1) ES2435651T3 (enExample)
HN (1) HN2012001160A (enExample)
HR (1) HRP20131052T1 (enExample)
IL (1) IL220011A (enExample)
JO (1) JO2978B1 (enExample)
MA (1) MA33824B1 (enExample)
MX (1) MX2012007332A (enExample)
MY (1) MY160618A (enExample)
NZ (1) NZ600305A (enExample)
PE (1) PE20121688A1 (enExample)
PH (1) PH12012501253A1 (enExample)
PL (1) PL2516406T3 (enExample)
PT (1) PT2516406E (enExample)
RS (1) RS53063B (enExample)
SG (1) SG181836A1 (enExample)
SI (1) SI2516406T1 (enExample)
TN (1) TN2012000281A1 (enExample)
TW (1) TWI477490B (enExample)
UA (1) UA107684C2 (enExample)
WO (1) WO2011084437A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2733221T3 (es) 2010-02-17 2019-11-28 Takeda Pharmaceuticals Co Compuesto heterocíclico
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
CN103209954B (zh) * 2010-11-18 2015-09-02 伊莱利利公司 作为mGluR2/3拮抗剂的4-取代的-3-苄氧基-双环[3.1.0]己烷化合物
PL2721012T3 (pl) 2011-06-17 2017-05-31 Eli Lilly And Company Pochodne kwasu bicyklo[3.1.0]heksano-2,6-dikarboksylowego jako agoniści receptora mglu2
AR089718A1 (es) * 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2015110435A1 (en) * 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) * 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5688826A (en) 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
US7038077B2 (en) * 2001-01-11 2006-05-02 Eli Lilly And Company Prodrugs of excitatory amino acids
US7256217B2 (en) * 2001-01-11 2007-08-14 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
WO2003104217A2 (en) * 2002-06-01 2003-12-18 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2005000790A1 (ja) * 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. 2-アミノビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸誘導体
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
CN103209954B (zh) * 2010-11-18 2015-09-02 伊莱利利公司 作为mGluR2/3拮抗剂的4-取代的-3-苄氧基-双环[3.1.0]己烷化合物

Also Published As

Publication number Publication date
JP2013514974A (ja) 2013-05-02
AU2010340039B2 (en) 2014-03-20
US8318184B2 (en) 2012-11-27
EP2516406B1 (en) 2013-09-18
PH12012501253A1 (en) 2014-08-01
DK2516406T3 (da) 2013-10-14
SG181836A1 (en) 2012-08-30
ES2435651T3 (es) 2013-12-20
SI2516406T1 (sl) 2013-11-29
MX2012007332A (es) 2012-07-20
EA020229B1 (ru) 2014-09-30
NZ600305A (en) 2014-01-31
MY160618A (en) 2017-03-15
PL2516406T3 (pl) 2014-03-31
CN102695701A (zh) 2012-09-26
PE20121688A1 (es) 2012-12-05
DOP2012000173A (es) 2012-11-30
TW201144290A (en) 2011-12-16
BR112012017188B1 (pt) 2021-06-22
HK1171228A1 (en) 2013-03-22
IL220011A0 (en) 2012-07-31
AR079343A1 (es) 2012-01-18
JO2978B1 (en) 2016-03-15
CN102695701B (zh) 2014-10-01
PT2516406E (pt) 2013-10-10
WO2011084437A1 (en) 2011-07-14
CA2784667A1 (en) 2011-07-14
BR112012017188A2 (pt) 2016-03-22
UA107684C2 (xx) 2015-02-10
RS53063B (sr) 2014-04-30
ECSP12011989A (es) 2012-07-31
EA201290558A1 (ru) 2012-12-28
CY1114880T1 (el) 2016-12-14
KR101395356B1 (ko) 2014-05-14
IL220011A (en) 2014-03-31
US20110152334A1 (en) 2011-06-23
TN2012000281A1 (en) 2013-12-12
BR112012017188A8 (pt) 2016-10-04
CA2784667C (en) 2014-11-18
JP5779190B2 (ja) 2015-09-16
HN2012001160A (es) 2015-08-24
TWI477490B (zh) 2015-03-21
CR20120322A (es) 2012-07-10
EP2516406A1 (en) 2012-10-31
HRP20131052T1 (hr) 2013-12-06
AU2010340039A1 (en) 2012-08-09
KR20120094056A (ko) 2012-08-23

Similar Documents

Publication Publication Date Title
MA33824B1 (fr) Agonistes du recepteur mglu2
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
EP2571360A4 (en) METHOD AND FORMULATIONS FOR OXYTOCIN TREATMENT OF DRUG ABUSE AND PSYCHIATRIC AND OTHER DISORDERS
MA34839B1 (fr) Dihydrofuranes condensés en tant que modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles apparentes
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA37940B1 (fr) Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses.
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
SG178997A1 (en) Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
MA37943B1 (fr) 2-oxo-2,3-dihydro-indoles destinés au traitement de troubles du snc
MA33428B1 (fr) Agonistes du gpr119
FR2981934B1 (fr) Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
EA201590854A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2
IN2015DN03145A (enExample)
MX2011012669A (es) Nuevos agonistas del receptor de glucocorticoides.
UA109260C2 (uk) Хромонові похідні, спосіб їх одержання та їх терапевтичні застосування
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
MA37990B1 (fr) Benzamides
MA28987B1 (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
IN2014CN03854A (enExample)
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
DE602008003221D1 (de) Prolinamidderivate als nk3-antagonisten
FR2981936B1 (fr) Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.